Here are Friday's biggest analyst calls: Nvidia, SpaceX, AMD, Broadcom, Warby Parker, Adobe, Kratos & more

Wall Street call activity is broadly constructive, with multiple upgrades and initiations including SpaceX, AMD, Nvidia, Broadcom, Williams-Sonoma, and Kratos Defense. The most notable bullish calls center on AI/GPU upside at AMD and Nvidia, while healthcare and consumer names such as Avalo Therapeutics, Guardant Health, and Williams-Sonoma also received favorable coverage. There is one meaningful negative call, with Stifel downgrading Adobe to hold on post-earnings catalysts and leadership uncertainty.

Analysis

The common thread is not “positive analyst action,” but a rotation toward businesses with pricing power, scarcity, or embedded operating leverage that can compound even if growth stays only mid-single digit. The market is rewarding names where the next leg of upside comes from mix, capacity, or strategic positioning rather than headline demand alone: semis tied to AI acceleration, consumer brands with resilience, and infrastructure-like cash flows with visible reinvestment runways. That favors stocks with self-help or moat expansion over the next 6-12 months, while anything dependent on perfect execution or multiple expansion without near-term catalysts is vulnerable.

The biggest second-order beneficiary is NVDA/AMD adjacency: any affirmation that AMD can gain share in GPUs is not just a single-stock call, it pressures the “winner-takes-all” assumption embedded in AI supply-chain baskets. If AMD is credible as a second source, suppliers, networking, and memory vendors become less dependent on one platform cycle, which can sustain capex longer but compress differentiation premiums for the pure plays. On the other side, ADBE’s downgrade is a warning that software leaders with muddier product transitions and leadership uncertainty can de-rate quickly when the market stops believing in durable margin defense.

In consumer, the more interesting trade is not merely “resilient spending,” but which companies can capture trade-down and premiumization simultaneously. WSM, CCEP, CELH/KDP, and WRBY all benefit from different versions of that thesis: either higher willingness to pay, better route-to-market, or a category tailwind that is insulated from broader discretionary softness. The risk is that several of these are already getting consensus love; if the next inflation print re-accelerates or consumer credit weakens, the market will quickly discriminate between true share gainers and names borrowing growth from price or distribution expansion.

Key Decisions for Investors

• Long AMD vs short ADBE, 3-6 month horizon: express a relative-growth / execution-quality trade; AMD has a credible catalyst stack into AI GPU share gains, while ADBE faces a longer repair cycle and leadership overhang.
• Add NVDA on pullbacks, but hedge with a small short basket of AI-adjacent software names for 1-3 months: the risk is not NVDA fundamentals, but multiple compression if the market broadens leadership beyond the obvious winner.
• Buy WSM and CCEP on weakness, 6-12 month hold: both have pricing/mix durability and should outperform if the market re-rates compounders with visible cash conversion; pair against a weaker consumer discretionary basket to isolate idiosyncratic alpha.
• Trade CELH/KDP as a category pair, 3-6 months: long the cleaner growth/margin inflection, short the more mature beneficiary if energy drink demand stays strong but valuation discipline reasserts itself.
• Treat GH and AVTX as event-driven optionality only: use small starter positions or call spreads into catalyst windows, with strict size limits because downside is dominated by timing risk rather than valuation.